AIMM Therapeutics (NL)

AIMM’s mission is to develop highly efficacious human monoclonal antibodies to prevent or treat diseases with high unmet medical need.

AIMM has developed very efficient and highly flexible toolbox of generating and producing fully human antibodies with desired properties. These proprietary antibodies are derived directly from B cells from selected exposed individuals.